the present disclosure provides a method of treatment of parkinsons disease, comprising the simultaneous or sequential introduction to a patient in need of treatment b \u043e\u043b\u0435\u0437\u043d\u0438 parkinson dosed formincluding (i) on l-dopa in a number \u0432\u0430\u0440\u044c\u0438\u0440\u0443\u044e\u0449\u0435\u043c from 50 to 300 mg (ii) \u043a\u0430\u0440\u0431\u0438\u0434\u043e\u043f\u0443 quantity \u0432\u0430\u0440\u044c\u0438\u0440\u0443\u044e\u0449\u0435\u043c from 25 to 150 mg.or \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438 equivalent of another inhibitor of aromatic amino acid carboxy lyases and (iii) \u044d\u043d\u0442\u0430\u043a\u0430\u043f\u043e\u043d quantity \u0432\u0430\u0440\u044c\u0438\u0440\u0443\u044e\u0449\u0435\u043c from 50 mg to 300 mgthe ratio of \u044d\u043d\u0442\u0430\u043a\u0430\u043f\u043e\u043d\u0430 and \u043a\u0430\u0440\u0431\u0438\u0434\u043e\u043f\u044b the dosed form varies from 0.3, 1.0 to 3.2: 1.0 mass, moderately active inhibitor \u0441\u043e\u043c\u0442 quantity \u0432\u0430\u0440\u044c\u0438 \u0440\u0443\u044e\u0449\u0435\u043c from 25 to 200 mg.the ratio of the inhibitor \u0441\u043e\u043c\u0442 and \u043a\u0430\u0440\u0431\u0438\u0434\u043e\u043f\u044b the dosed form varies from 0.16: 1.0 to 3.08: 1.0, mass, or highly active inhibitor \u0441\u043e\u043c\u0442 quantity\u0432\u0430\u0440\u044c\u0438\u0440\u0443\u044e\u0449\u0435\u043c from 1 to 100 mg, with the ratio of the inhibitor \u0441\u043e\u043c\u0442 and \u043a\u0430\u0440\u0431\u0438\u0434\u043e\u043f\u044b the dosed form varies from 0.006: 1.0 to 1.54: 1.0 mass flow rate.also disclosed \u0434\u043e\u0437\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u0430\u044f form used in this method.Настоящее раскрытие предоставляет способ лечения болезни Паркинсона, включающий одновременное или последовательное введение пациенту, нуждающемуся в лечении болезни Паркинсона, дозированной формы, включающей (i) леводопу в количестве, вар
